Read twice and referred to the Committee on the Judiciary.
Source-heavy congressional process material lives here so the main bill summary can stay focused. Use this tab for committee scheduling, hearings, CRS analysis, committee publications, and amendment text.
Nonpartisan Congressional Research Service analysis linked directly to this bill.
Nonpartisan background and policy analysis tied directly to this bill.
New “brand-name” drugs are often protected from generic competition by patents. In general, a drug manufacturer intending to market a generic version of a brand-name drug must either wait for those patents to expire or challenge the validity or applicability of the patents in court. While some drug patents cover the a…
Scheduled or recent committee meetings that mention this bill, plus agenda materials and witness documents.
No committee meetings linked to this bill yet.
Hearings, transcripts, and related meeting references associated with this bill.
No hearings linked to this bill yet.
Formal committee rationale and report language published for this bill.
No committee reports linked to this bill yet.
Working packets, committee print materials, and related draft text.
No committee prints linked to this bill yet.
Structured amendment records, latest actions, vote references, and text links.
No amendments linked to this bill yet.